Home » Stocks » CymaBay Therapeutics

CymaBay Therapeutics Inc. (CBAY)

Stock Price: $6.26 USD 0.53 (9.25%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $6.20 -0.06 (-0.96%) Aug 7, 7:59 PM

Stock Price Chart

Key Info

Market Cap 431.20M
Revenue (ttm) n/a
Net Income (ttm) -92.82M
Shares Out 68.88M
EPS (ttm) -1.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $6.26
Previous Close $5.73
Change ($) 0.53
Change (%) 9.25%
Day's Open 5.68
Day's Range 5.67 - 6.30
Day's Volume 5,422,641
52-Week Range 1.21 - 6.56

More Stats

Market Cap 431.20M
Enterprise Value 256.60M
Earnings Date (est) Aug 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 68.88M
Float 55.55M
EPS (basic) -1.35
EPS (diluted) -1.35
FCF / Share -1.31
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 8.08M
Short Ratio 5.09
Short % of Float 11.66%
Beta 1.36
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.92
Revenue n/a
Operating Income -97.83M
Net Income -92.82M
Free Cash Flow -90.36M
Net Cash 174.60M
Net Cash / Share 2.53
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -25.04%
ROE -42.91%
ROIC -55.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (10)

Buy 10
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$11.90*
(90.10% upside)
Low
7.00
Current: $6.26
High
20.00
Target: 11.90
*Average 12-month price target from 10 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue--10.00----3.0515.15
Revenue Growth--------79.86%-
Gross Profit--10.00----3.0515.15
Operating Income-108-72.51-21.33-25.59-25.90-24.01-9.40-10.44-3.90
Net Income-103-72.55-27.56-26.67-15.53-31.92244-23.90-4.50
Shares Outstanding67.0357.8134.9023.4518.9012.052.360.010.01
Earnings Per Share-1.53-1.26-0.79-1.14-0.83-2.65-3.54-4,128.71-2,963.11
Operating Cash Flow-97.91-54.94-19.63-23.35-23.32-21.11-8.46-11.29-17.93
Capital Expenditures-0.32-0.53-0.03-0.04--0.100.66--0.04
Free Cash Flow-98.23-55.47-19.66-23.40-23.32-21.22-7.80-11.29-17.96
Cash & Equivalents19117997.2116.9941.4834.8031.247.7319.03
Total Debt1.74-6.108.809.314.514.4513.7413.76
Net Cash / Debt18917991.118.2032.1730.2926.80-6.015.27
Assets20618710419.3643.0837.4732.508.1219.79
Liabilities19.3816.3319.3015.4214.9623.6213.9017.9918.55
Book Value18617084.953.9428.1213.8518.60-329-305
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name CymaBay Therapeutics Inc.
Country United States
Employees 36
CEO Sujal Shah

Stock Information

Ticker Symbol CBAY
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CBAY

Description

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis and sclerosing cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type 2 diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.